Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct;10(10):1885-1892.
doi: 10.1111/1759-7714.13158. Epub 2019 Aug 6.

Effect of medical thoracoscopy-guided intrapleural docetaxel therapy to manage malignant pleural effusion in patients with non-small cell lung cancer: A pilot study

Myeong Geun Choi  1 , Sojung Park  2 , Dong Kyu Oh  1 , Hyeong Ryul Kim  3 , Geun Dong Lee  3 , Jae Cheol Lee  4 , Chang-Min Choi  1   4 , Wonjun Ji  1
Affiliations

Effect of medical thoracoscopy-guided intrapleural docetaxel therapy to manage malignant pleural effusion in patients with non-small cell lung cancer: A pilot study

Myeong Geun Choi et al. Thorac Cancer. 2019 Oct.

Abstract

Background: Although chemical pleurodesis is a useful treatment option for malignant pleural effusion, little is known about the effects of intrapleural docetaxel therapy.

Objectives: This study aimed to evaluate the effects of medical thoracoscopy-guided intrapleural docetaxel therapy in patients with lung cancer.

Methods: Patients with lung cancer who diagnosed malignant pleural effusion were enrolled in this single-center prospective pilot study. The clinical response and toxicity were evaluated at two, six and 12 weeks post-treatment.

Results: Medical thoracoscopy-guided intrapleural docetaxel therapy was conducted in four patients between June 2016 and August 2017. The control rate of malignant pleural effusion was 100% (4/4), and the progression-free duration of effusion was 527 ± 109 days. No serious adverse events were observed, but only mild-to-moderate adverse events were observed and well controlled by conservative management. Although the overall quality of life assessed using questionnaires did not show significant improvement, symptom burden due to dyspnea was significantly improved.

Conclusions: Intrapleural docetaxel therapy with medical thoracoscopy showed good clinical responses, relieving dyspnea symptoms and providing tolerable safety profiles in patients with non-small cell lung cancer (NSCLC) with malignant pleural effusion. A further prospective trial is warranted to evaluate the clinical effects of intrapleural docetaxel therapy in order to compare it with other treatment modalities.

Keywords: Docetaxel; malignant pleural effusion; pleurodesis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Consort flow diagram of the study.
Figure 2
Figure 2
Overall response curve of intrapleural docetaxel therapy.
Figure 3
Figure 3
(a) Overall survival curve of patients with non‐small cell lung cancer with malignant pleural effusion. (b) Progression of disease free survival and progression of effusion free survival.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Lorenzo MJ, Modesto M, Perez J et al Quality‐of‐life assessment in malignant pleural effusion treated with indwelling pleural catheter: A prospective study. Palliat Med 2014; 28: 326–34. - PubMed
    1. Dhaliwal I, Mahdavian M, Asghari S et al Management of malignant pleural effusion with ASEPT® pleural catheter: Quality of life, feasibility, and patient satisfaction. Can Respir J 2016; 2016: 4273480. - PMC - PubMed
    1. Thomas JM, Musani AI. Malignant pleural effusions: A review. Clin Chest Med 2013; 34: 459–71. - PubMed
    1. Psallidas I, Kalomenidis I, Porcel JM, Robinson BW, Stathopoulos GT. Malignant pleural effusion: From bench to bedside. Eur Respir Rev 2016; 25: 189–98. - PMC - PubMed
    1. Feller‐Kopman DJ, Reddy CB, DeCamp MM et al Management of malignant pleural effusions. An official ATS/STS/STR clinical practice guideline. Am J Respir Crit Care Med 2018; 198: 839–49. - PubMed

Publication types

MeSH terms